1. Medicines
  2. Respiratory and Inflammation
  3. ATECTURA® BREEZHALER® (indacaterol acetate/mometasone furoate inhalation powder)
  4. The inhaler device

Prescribing information

 

The inhaler device

   

For patients on ICS monotherapy, ATECTURA® BREEZEHALER® (indacaterol acetate/mometasone furoate inhalation powder) long-acting beta2-agonist (LABA)/inhaled corticosteroid (ICS) (IND/MF) is available in three dierent doses: low, medium and high*.1
 

 

How to use the BREEZHALER device

Watch the following video to learn how to use the BREEZHALER.

 

 

*ATECTURA BREEZHALER high-dose = IND/MF 150/320 μg (once-daily); ATECTURA BREEZHALER medium-dose = IND/MF 150/160 μg (once-daily); ATECTURA BREEZHALER low-dose = IND/MF 150/80 μg (once-daily).

IND, indacaterol; MF, mometasone furoate; AE, adverse event; SAE, serious adverse event.

Reference

  1. ATECTURA BREEZEHALER Summary of Product Characteristics.
     
ATE20-C003 November 2020.
Respiratory and Inflammation
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]